Boston Scientific Announces Results For Fourth Quarter And Full Year 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Boston Scientific (BSX) Tops Q4 EPS by 2c; Offers Q1 EPS Guidance Below Consensus, FY20 EPS Mid-Point Outlook Below Consensus
February 5, 2020 6:34 AM ESTBoston Scientific (NYSE: BSX) reported Q4 EPS of $0.46, $0.02 better than the analyst estimate of $0.44. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.92 billion.
"We delivered strong revenue and adjusted EPS growth for the quarter and the year by developing innovative products, executing on our category leadership strategy and mitigating challenges," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We're confident that we have the pipeline, leadership team and focused execution to deliver on our goals to address unmet clinical needs and work to improve the lives of... More
